Evidence map›Paper›PMID 30061278›Full record

ArticleAntimicrobial agents and chemotherapy2018

Sensitivity of the C-Terminal Nuclease Domain of Kaposi's Sarcoma-Associated Herpesvirus ORF29 to Two Classes of Active-Site Ligands.

Jennifer T Miller, Haiyan Zhao, Takashi Masaoka, Brittany Varnado, Elena M Cornejo Castro, Vickie A Marshall, Kaivon Kouhestani, Anna Y Lynn, Keith E Aron, Anqi Xia and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Jennifer T MillerBasic Research Laboratory, National Cancer Institute, Frederick, Maryland, USA.
Haiyan ZhaoDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas, USA.
Takashi MasaokaBasic Research Laboratory, National Cancer Institute, Frederick, Maryland, USA.
Brittany VarnadoDepartment of Chemistry, Brooklyn College, City University of New York, Brooklyn, New York, USA.
Elena M Cornejo CastroViral Oncology Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, USA.
Vickie A MarshallViral Oncology Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, USA.
Kaivon KouhestaniBasic Research Laboratory, National Cancer Institute, Frederick, Maryland, USA.
Anna Y LynnDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas, USA.
Keith E AronDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas, USA.
Anqi XiaDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas, USA.
John A BeutlerMolecular Targets Program, National Cancer Institute, Frederick, Maryland, USA.
Danielle R HirschDepartment of Chemistry, Brooklyn College, City University of New York, Brooklyn, New York, USA.
Liang TangDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas, USA.
Denise WhitbyViral Oncology Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, USA.
Ryan P MurelliDepartment of Chemistry, Brooklyn College, City University of New York, Brooklyn, New York, USA.
Stuart F J Le GriceBasic Research Laboratory, National Cancer Institute, Frederick, Maryland, USA legrices@mail.nih.gov.
University of Kansas · USFrederick National Laboratory for Cancer Research · USNational Cancer Institute · USBrooklyn College · USCity University of New York · USTarget (United States) · US

Funding

Development of Natural Product Leads as Anticancer TherapeuticsZIABC011470 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BEUTLER, JOHN · 2012 to 2025
$7.8M
Development and Exploitation of New Synthetic Strategies for TropolonesSC1GM111158 · NIGMS · BROOKLYN COLLEGE · PI MURELLI, RYAN · 2015 to 2023
$3.1M
Genome packaging in DNA virusesR01GM090010 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI TANG, LIANG · 2010 to 2014
$1.3M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIGMS NIH HHS R01 GM090010NIGMS NIH HHS SC1 GM111158
6 · The paper itself

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV), the etiological agent of Kaposi's sarcoma, belongs to the

Indexed as

Calorimetry, Differential ScanningCatalytic DomainDNA, ViralEndodeoxyribonucleasesEndonucleasesEnzyme ActivationHerpesvirus 8, HumanHIV Integrase InhibitorsIntegrasesMutagenesis, Site-DirectedOpen Reading FramesProtein Structure, SecondaryRibonuclease HSarcoma, KaposiDNA, ViralEndodeoxyribonucleasesEndonucleasesHIV Integrase InhibitorsIntegrasesRibonuclease Hterminaseactive-site mutagenesisDNA packagingKaposi's sarcoma-associated herpesvirusnucleaseterminaseα-hydroxytropolone

Identifiers

PMID30061278
PMCPMC6153795
OpenAlexW2884206706

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.